Economic Daily News / Reporter Po-Hong Hsieh U-NEURON (6973) held its “Intelligent Integrated Exosome Design & Manufacturing Platform and Next-Generation Regenerative Medicine Applications Launch Event” on the 22nd.

YonglirongThe event attracted nearly 200 participants from academic R&D, clinical medicine, consumer healthcare brands, and the investment community, witnessing the exosome industry enter a new era of platformization and customized design. The “Intelligent Integrated Exosome Design and Manufacturing Platform and Next-Generation Regenerative Medicine Application Conference” was held on the 22nd, attracting nearly 200 people from academic research and development, medical experts, consumer health care brands and investment circles to witness the exosome industry entering a new era of “platformization” and “customized design”.

This press conference brought together important representatives from industry, government, academia and research, including former Minister of Economic Affairs Guo Zhihui, Chairman of the Taiwan African Economic and Trade Association Huang Zhipeng, and Laifeng-KYThe event brought together prominent representatives across government, industry, academia, and research, including former Minister of Economic Affairs Kuo Jyh-huei, Taiwan-Africa Economic and Development Association Chairman Huang Chih-peng, Chlitina Group (4137) Chairwoman Chen Pi-hua, and Asia-Pacific Aesthetic Surgery Group Superintendent Dr. Tseng Wen-shang, marking a major milestone for Taiwan’s regenerative medicine and biotechnology sectors.Dignitaries such as Chen Bihua, chairman of the group, and Dr. Zeng Wenshang, general president of Taiwan’s well-known Yafeng Medical Group, came to witness the important milestones of Taiwan’s regenerative medicine and biotechnology industry.

Former Economic Affairs Minister Kuo Jyh-huei stated that global biomedical technology is entering a new era of regenerative medicine and precision healthcare, with exosomes emerging as a critical core technology. Taiwan previously established world-class competitive advantages in the semiconductor sector through the “Design × Manufacturing” model; this framework is now extending into the life sciences to drive industrial upgrading and value creation. He noted that the “Onshore-Offshore” international healthcare strategy promoted during his tenure aims to build Taiwan into a global medical and biotech innovation hub, accelerating the international rollout of domestic technologies, products, and services.

Huang Chih-peng highlighted that rapidly growing healthcare demand across emerging markets in Southeast Asia and Africa offers significant international expansion opportunities for Taiwan’s biomedical industry. As global competition shifts from single-product exports to integrated “Technology × Application × Market” capabilities, U-NEURON’s i-ExoCraft® platform exhibits high cross-domain integration potential, connecting medical, aesthetic, and healthcare markets while serving as a vital interface for Taiwan to link with global markets and deepen local collaboration.

Superintendent Dr. Tseng Wen-shang emphasized: “As society ages globally, regenerative medicine has become an inevitable trend in healthcare. We are no longer merely filling the traces of aging, but leveraging advanced technologies like U-NEURON’s i-ExoCraft® platform to precisely reactivate the native vitality of skin and tissue at the cellular level.”

U-NEURON Chairman Dr. Frank Chien stated that U-NEURON is the world’s first company to secure U.S. patents for isolation and culture technologies of amniotic fluid stem cells, as well as the only biotech firm in Asia built around an amniotic fluid stem cell core. Deeply rooted in regenerative medicine, the company has accumulated an extensive patent portfolio in amniotic fluid stem cell isolation and culture, establishing an R&D platform supporting novel therapeutics, cosmeceuticals, and functional health food product lines.

In novel drug development, U-NEURON’s lead program for erectile dysfunction (UA002), designed around neural repair mechanisms, has advanced into Phase 2a clinical trials. Following the official implementation of the tworegenerativemedicinelaws this year, the company stands as a key policy beneficiary, having secured TFDAproject-basedadvisory guidance and CDEflagshipcasestatus—adualexpeditedregulatorypathway for regenerative medicine.

On commercial operations, U-NEURON actively develops deer-derived exosome ingredients and velvet antler polypeptide health ingredients, serving as a primary raw material supplier and OEM/ODM manufacturing partner for cosmetic brands under the Chlitina Group and health food leaders such as Yamato Bio, generating steady year-over-year revenue growth. To further strengthen operational momentum, U-NEURON launched its Exosome R&D Pilot Manufacturing Center in Hsinchu last year, adopting an Exosome Design House business model to provide clients with tailored OEM/ODM product design and manufacturing services.

The newly unveiled i-ExoCraft® platform represents an upgraded service model that formally introduces the semiconductor “Design House × Foundry” paradigm into the exosome domain. Exosomes transition from standard raw material supplies into biological carriers capable of functional customization and engineered design. This advances exosome technology into a design-oriented phase with broad applications across medical aesthetics, regenerative therapeutics, functional nutraceuticals, and veterinary healthcare.

U-NEURON’s expansion formally marks the transition of the exosome industry from a raw material supply orientation toward function-driven product design. By leveraging strong cross-domain integration and market competitiveness, U-NEURON continues to advance Taiwan’s regenerative medicine capabilities across global markets, deepening local and international connections to expand its market influence as a leading figure in Taiwan’s regenerative medicine sector.

Tseng Wen-shang, and U-NEURON President Dr.
Hsiao-Min Huang.
Photo / Provided by U-NEURON
U-NEURON Intelligent Integrated Exosome Design & Manufacturing Platform and Next-Generation Regenerative Medicine Applications Launch Event Group Photo: (From left) U-NEURON Chief Operating Officer Shin-Yi Chuang, Taiwan-Africa Economic and Development Association Chairman Huang Chih-peng, Former Minister of Economic Affairs Kuo Jyh-huei, U-NEURON Chairman Dr. Frank Chien, Chlitina Group Chairwoman Chen Pi-hua, Asia-Pacific Aesthetic Surgery Group Superintendent Dr.

https://money.udn.com/money/story/5612/9396518?from=edn_newest_index